Mavyret, Maviret(pibrentasvir)
Maviret, Mavyret (pibrentasvir) is a small molecule pharmaceutical. Pibrentasvir was first approved as Maviret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Mavyret
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mavyret | New Drug Application | 2020-05-08 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GLECAPREVIR / PIBRENTASVIR, MAVYRET, ABBVIE | |||
| 2028-12-10 | PED | ||
| 2028-06-10 | ODE-372 | ||
| 2026-10-30 | PED | ||
| 2026-04-30 | ODE-232, ODE-233 | ||
| 2023-10-10 | PED | ||
| 2023-04-10 | M-259 | ||
| 2023-03-26 | PED | ||
| 2023-02-03 | PED | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Glecaprevir / Pibrentasvir, Mavyret, Abbvie | |||
| 11246866 | 2036-06-24 | DP | |
| 9321807 | 2035-06-05 | DP | |
| RE48923 | 2035-05-08 | DP | |
| 10286029 | 2034-03-14 | U-3237, U-3238 | |
| 11484534 | 2034-03-14 | U-3237 | |
| 8937150 | 2032-05-18 | DS, DP | |
| 8648037 | 2032-01-19 | DS, DP | U-2141, U-3237, U-3238 |
| 9586978 | 2030-11-06 | U-2141, U-3237, U-3238 | |
| 10028937 | 2030-06-10 | U-2141, U-3237, U-3238 | |
| 10039754 | 2030-06-10 | U-2141, U-3237, U-3238 | |
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | B19.2 | 1 | 7 | 16 | 10 | 5 | 34 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 5 | 12 | 2 | 1 | 18 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 2 | 1 | — | 3 | — | 5 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | 2 | — | 3 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 2 | — | 2 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | 1 | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepacivirus | D016174 | — | 5 | 8 | — | — | 11 | ||
| Hepatitis b | D006509 | 1 | 1 | 3 | — | 1 | 5 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 2 | — | 1 | 4 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | 2 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 1 | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
| Rna virus infections | D012327 | — | — | — | — | 1 | 1 | ||
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | — | — | — | 1 | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | — | 1 | 1 |
| Viral hepatitis human | D006525 | EFO_0004196 | — | — | — | — | 1 | 1 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Hiv | D006678 | O98.7 | — | — | — | — | 1 | 1 | |
| Risk reduction behavior | D040242 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PIBRENTASVIR |
| INN | pibrentasvir |
| Description | Pibrentasvir is an NS5A inhibitor antiviral agent. In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C. It is sold by Abbvie.
|
| Classification | Small molecule |
| Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc([C@H]3CC[C@H](c4cc5nc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)[C@@H](C)OC |
Identifiers
| PDB | — |
| CAS-ID | 1353900-92-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545123 |
| ChEBI ID | — |
| PubChem CID | 58031952 |
| DrugBank | DB13878 |
| UNII ID | 2WU922TK3L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Mavyret - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,486 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mavyret
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
46,376 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more